Figure 5.

(A) BFU-E numbers from two 5q- syndrome patients treated with lenalidomide. BFU-E numbers and percent 5q(del) clones for Patient 1 were 10 (71%) on day 0 of treatment, 600 (3%) at 4 months and 20 (83%) at 8 months. The corresponding figures for patient 2 were 9 (96%), 207 (33%), and 33 (70%), (B) Ex vivo proliferation of erythroid progenitors. CD34⁺ cells obtained at the same time-points were cultured for 18 days in a liquid medium according to a three-step protocol. Total cell numbers were counted. Results are expressed as fold-expansion on day 18 relative to day 0 and correlated with percent 5q(del) clones.